CN107935993A - Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use - Google Patents
Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use Download PDFInfo
- Publication number
- CN107935993A CN107935993A CN201711467947.3A CN201711467947A CN107935993A CN 107935993 A CN107935993 A CN 107935993A CN 201711467947 A CN201711467947 A CN 201711467947A CN 107935993 A CN107935993 A CN 107935993A
- Authority
- CN
- China
- Prior art keywords
- compound
- ssao
- nitropyridine
- preparation
- methyl adamantane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to SSAO inhibitor field.Specifically, the present invention relates to a kind of SSAO inhibitor containing methyl adamantane and nitropyridine class formation, its preparation method and the application in treatment diseases associated with inflammation, immunity disease and tumour etc. is prepared.
Description
Technical field
The present invention relates to the field of SSAO inhibitor.In particular it relates to there is therapeutic effect to suppressing SSAO
A kind of noval chemical compound containing methyl adamantane and nitropyridine structure, its preparation method, and the purposes in pharmacy.
Background technology
Semicarbazide-sensitive amine oxidizing ferment (semicarbazide-sensitive amine oxidase, SSAO) activity
It is by Vascular AdhesionProtein -1 (Vascular Adhesinon Protein-1, VAP-1) or copper-containing amine oxidases (Amone
Oxidase, Copper Containing 3, AOC3) enzymatic activity that is showed, the enzyme belongs to copper-containing amine oxidases family
(EC.1.4.3.6).Therefore, the inhibitor of SSAO enzymes also adjusts the biological function of VAP-1 albumen.The member of the enzyme family
Suppression to semicarbazides is sensitive, and by bivalent cupric ion and from protein hydroxydopa quinone (topa quinine,
TPQ) co-factor be used for from primary amine to aldehyde, the oxidative deamination of hydrogen peroxide and ammonia.
The known substrate of people SSAO includes endogenous methylamine and aminoacetone, and some exogenous amine such as benzylamines
(Lyles, Int.J.Biochem.Cell Biol., 1996,28,259-274).It is similar with other copper-containing amine oxidases, DNA sequences
Row analysis and structure determination show that the people SSAO combined with tissue is homodimeric glycoprotein, it is by two 90-100kDa's
Subunit forms, by single N-terminal transmembrane domain be anchored to plasma membrane (Morris, et al.J.Biol.Chem., 1997,272,
9388-9392)。
SSAO activity is had found in Various Tissues (including blood vessel and non-vascular smooth muscle tissue, endothelium and adipose tissue)
(Lewinsohn,Braz.J.Med.Biol.Res.,1984,17,223-256).In addition, SSAO albumen also found in blood plasma
And this soluble form seem with tissue combining form have similar performance (Kurkijarvi, et al.J.Immunol.,
1998,161,1549-1557).Recently it has been shown that SSAO derives from tissue combining form in the circulation of people and rodent
(Stolen,et al.Circ.Res.,2004,95(1),50-57)。
The precise physiological effect of this abundant enzyme is not yet fully defined, but seems SSAO and its reaction product thin
There may be several functionalities in born of the same parents' signal transduction and adjusting.For example, nearest discovery shows, the glucose that SSAO is mediated in GLUT4
Absorb (Morin, et al.J.Pharmacol.Exp.Ther., 2001,297,563-572) and Adipocyte Differentiation
All play a role in (Fontana, Biochem.J., 2001,356,769-777).In addition, SSAO also shows to participate in inflammation mistake
Journey, wherein SSAO serve as leucocyte adhesion protein (Salmi＆Jalkanen, Trends Immunol., 2001,22,211-
216) and be also possible to connective tissue matrix produce and maintain in play a role (Goktiirk, et al.Am.J.Pathol.,
2003,163(5),1921-1928).Moreover, having found recently (Noda, et are contacted between SSAO and angiogenesis
Al.FASEB J., 2008,22 (8), 2928-2935), and it is based on the contact, it is contemplated that SSAO inhibitor has anti-angiogenic generation
Effect.
Many researchs to the mankind are it has proven convenient that in such as congestive heart failure, diabetes, alzheimer disease and inflammation
Illness in, the rise of SSAO in blood plasma activity (del MarHernandez, et al.Neurosci.Lett., 2005,384
(1-2),183-187).The mechanism of these enzyme activity change behinds is not known.It has been proposed that produced by endogenous amine oxidases
Active aldehydes and hydrogen peroxide promote angiocardiopathy, development (Jiang, the et of diabetic complication and alzheimer disease
al.Neuropathol.Appl.Neurobiol.,2008,34(2),194-204).In addition, the enzymatic activity of SSAO is related to inflammation
The Leukocyte extravasation process at position, wherein SSAO have shown high expression on skin in the blood vessels.Therefore, it has been suggested that the suppression of SSAO
Agent has therapeutic value (Salter-Cid, et in prevention diabetic complication and inflammatory disease
al.J.Pharmacol.Exp.Ther.,2005,315(2),553-562)。
SSAO is raised in stomach cancer and in the tumor vascular system of human melanoma, hepatoma and H/N tumors
In be accredited (Forster-Horvath C, et al.Melanoma Res., 2004,14,135-140).One report
(Marttila-Ichihara F, et al.J.Immunol., 2010,184,3164-3173) has shown inactivating with enzyme
Melanoma growth is more slow in the mouse of SSAO, and its tumor vessel number and diameter are reduced.The growth of these tumours subtracts
The reduction that marrow sample suppresses cellular infiltration is also manifested in less.It is encouraging that SSAO defect normal tissue medium vesselses or lymph
Formation do not influence.
WO02/38153、WO 03/006003、WO 2005/014530、WO2007/120528、PCT/EP2009/
Some SSAO inhibitor are disclosed in 062011 and PCT/EP2009/062018.
The invention discloses a kind of noval chemical compound containing methyl adamantane and nitropyridine structure, these compounds can be used for
Prepare the medicine of the diseases such as diseases associated with inflammation, immunity disease and tumour.
The content of the invention
It is an object of the present invention to provide a kind of SSAO inhibitor with Formulas I.
It is a further object to provide the method for preparing the compound with Formulas I.
It is also another object of the present invention to provide the compound containing Formulas I treatment diseases associated with inflammation, immunity disease and
Application in terms of tumour.
Present invention is specifically described in conjunction with the purpose of the present invention.
Compound of the invention with formula (I) is with following structural formula：
Formula (I) compound of the present invention can be synthesized by following route：
Compound III can according to document (Hulin, B., et al.Bioorg.Med.Chem.Lett., 2005,15,
4770-4773) method synthesizes.
Dibromide II and cyclic amine III is alkali, Pd (OAc) in t-BuOK2The lower coupling of/BINAP catalysis, obtains compound
IV；IV and amantadine V is alkali, Pd (OAc) in t-BuOK2It is coupled again under/BINAP catalysis, obtains compound I.
Compound of formula I of the present invention has SSAO inhibitory action, can be used to prepare as active ingredient such as inflammatory disease
The medicine of the diseases such as disease, immunity disease and tumour.The activity of compound of formula I of the present invention is by suppressing in vitro
SSAO is tested to verify.
Embodiment
With reference to embodiment, the present invention is further illustrated.It should be noted that following embodiments are only for
Illustrate, and be not intended to limit the present invention.General technical staff's training centre according to the present invention in the art is made various
Change should all be within the protection domain required by the application claim.
The synthesis of 1 compound I-1 of embodiment
The synthesis of step 1. compound IV-1
Compound II-1 (2.37g, 10mmol), compound III (1.07g, 10mmol), Pd (OAc)2(0.22g,
1mmol), BINAP (2,2'- double diphenylphosphino -1,1'- dinaphthalenes, 0.62g, 1mmol) and t-BuOK (2.24g, 20mmol) add
Enter 1, the 2- dimethoxy-ethanes (DME) to 50mL dryings, reaction mixture is stirred overnight in a nitrogen atmosphere, TLC detection hairs
Now reaction is completed.
Reaction mixture is carefully poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, according to
Secondary 1% dilute hydrochloric acid and salt water washing, anhydrous sodium sulfate drying.Filtering and remove drier, filtrate is evaporated on a rotary evaporator,
Residue is purified using silica gel column chromatography, obtains compound IV-I, 1.76g (yield 67%).ESI-MS, m/z=264 ([M+H
]+)。
The synthesis of step 2. compound I-1
Compound IV-1 (1.32g, 5mmol), compound V-1 (0.83g, 5mmol), Pd (OAc)2(0.11g,
0.5mmol), BINAP (0.31g, 0.5mmol) and t-BuOK (1.12g, 10mmol) is added to the 1,2- dimethoxies of 20mL dryings
Base ethane (DME), reaction mixture is stirred overnight in a nitrogen atmosphere, and TLC detections find that reaction is completed.
Reaction mixture is carefully poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, according to
Secondary 1% dilute hydrochloric acid and salt water washing, anhydrous sodium sulfate drying.Filtering and remove drier, filtrate is evaporated on a rotary evaporator,
Residue is purified using silica gel column chromatography, obtains compound I-I, 1.17g (yield 70%).ESI-MS, m/z=348 ([M+H
]+), white powder.
The synthesis of 2 compound I-2 of embodiment
The synthesis of step 1. compound IV-2
Compound II-2 (2.62g, 10mmol), compound III (1.07g, 10mmol), Pd (OAc)2(0.22g,
1mmol), BINAP (2,2'- double diphenylphosphino -1,1'- dinaphthalenes, 0.62g, 1mmol) and t-BuOK (2.24g, 20mmol) add
Enter 1, the 2- dimethoxy-ethanes (DME) to 50mL dryings, reaction mixture is stirred overnight in a nitrogen atmosphere, TLC detection hairs
Now reaction is completed.
Reaction mixture is carefully poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, according to
Secondary 1% dilute hydrochloric acid and salt water washing, anhydrous sodium sulfate drying.Filtering and remove drier, filtrate is evaporated on a rotary evaporator,
Residue is purified using silica gel column chromatography, obtains compound IV-2.ESI-MS, m/z=289 ([M+H]+)。
The synthesis of step 2. compound I-2
Compound IV-2 (1.44g, 5mmol), compound V-1 (0.83g, 5mmol), Pd (OAc)2(0.11g,
0.5mmol), BINAP (0.31g, 0.5mmol) and t-BuOK (1.12g, 10mmol) is added to the 1,2- dimethoxies of 20mL dryings
Base ethane (DME), reaction mixture is stirred overnight in a nitrogen atmosphere, and TLC detections find that reaction is completed.
Reaction mixture is carefully poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, according to
Secondary 1% dilute hydrochloric acid and salt water washing, anhydrous sodium sulfate drying.Filtering and remove drier, filtrate is evaporated on a rotary evaporator,
Residue is purified using silica gel column chromatography, obtains compound I-2.ESI-MS, m/z=373 ([M+H]+), white solid.
3 Compound ira vitro of embodiment suppresses SSAO analyses
All Preliminary Determinations are all to be carried out at room temperature using purified recombination expression people SSAO.Substantially such as
Enzyme is prepared described in Ohman etc. (Protein Expression and Purification, 2006,46,321-331).This
Outside, two level and selectively measuring is carried out using from SSAO made from Various Tissues or purified rat recombinant SSAO.Use benzyl
Amine is produced to measure enzymatic activity as substrate by using the hydrogen peroxide in horseradish peroxidase (HRP) coupling reaction.Letter
For it, will test compound to be dissolved in dimethyl sulfoxide (DMSO) (DMSO) to concentration be 10mM.By carrying out 1 in DMSO:10
Be serially diluted to produce 7 point curves or by carrying out 1 in DMSO:3 be serially diluted measures agent to produce 11 point curves
Amount-response measurement value.Maximum concentration is adjusted according to the potency of compound, is then diluted, obtains in reaction buffer
DMSO final concentration≤2%.
Hydrogen peroxide detects：In horseradish peroxidase (HRP) coupling reaction, by 10- acetyl group -3,7- dihydroxy fens
Piperazine (10-acetyl-3,7-dihydroxyphenoxazine) generates resorufin (resorufin) with hydrogen peroxide oxidation,
Resorufin be a kind of high-efficiency fluorescence compound (Zhout and Panchuk-Voloshina, Anal.Biochem., 1997,253,
169-174；Red hydrogen peroxide/peroxidase determination kit, Invitrogen A22188).By adding HRP, benzyl
Before the mixture of amine and Amplex reagents starts reaction, by the enzyme in 50mM sodium phosphates (pH 7.4) and compound flat micro-
Measure preincubate about 15 minutes in titer plate.The concentration of benzylamine is set to correspond to the concentration of Michaelis constant, it uses standard side
Method measures.Then during 1-2 hour, in several point in time measurement fluorescence intensities, excited and at 590nm at 544nm
Read transmitting.Final concentration is measured for the people SSAO of reagent in measure hole：1 μ g/mL of SSAO enzymes, 100 μM of benzylamine, Amplex reagents
20 μM, HRP 0.1U/mL and the various concentrations for testing compound.Inhibitory action is measured as with not having inhibitor (only diluted
DMSO the signal) compared reduces percentage.The background signal from the sample without SSAO enzymes is subtracted from all data points.Will
Data are fitted to four parameter logistic models, and calculate IC using 4 programs of GraphPad Prism50Value.
As a result see the table below.
| Compound | IC50(nM) |
| Compound I-1 | 74.5 |
| Compound I-2 | 16.1 |
The compound that can be seen that the present invention from upper table result has very strong inhibitory action to SSAO, can be used as system
The medicine of the diseases such as standby diseases associated with inflammation, immunity disease and tumour.
Claims (3)
1. the compound with logical formula (I) structure,
2. synthesize the method for compound described in claim 1：
Dibromide II and cyclic amine III is alkali, Pd (OAc) in t-BuOK2The lower coupling of/BINAP catalysis, obtains compound IV；IV
With amantadine V alkali, Pd (OAc) are in t-BuOK2It is coupled again under/BINAP catalysis, obtains compound I.
3. application of the compound described in claim 1 in terms for the treatment of diseases associated with inflammation, immunity disease and tumour medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711467947.3A CN107935993A (en) | 2017-12-29 | 2017-12-29 | Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711467947.3A CN107935993A (en) | 2017-12-29 | 2017-12-29 | Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107935993A true CN107935993A (en) | 2018-04-20 |
Family
ID=61937839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711467947.3A Pending CN107935993A (en) | 2017-12-29 | 2017-12-29 | Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107935993A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11472769B2 (en) | 2019-10-29 | 2022-10-18 | Eccogene (Shanghai) Co., Ltd. | SSAO inhibitors and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| WO2004024711A1 (en) * | 2002-09-10 | 2004-03-25 | Pharmacia Italia S.P.A. | Substituted pyridine derivatives as antitumor agent |
| CN1520290A (en) * | 2001-07-12 | 2004-08-11 | �Ƹ��� | Carbocyclic hydrorazino inhibitors of copper-containing amine oxidases |
| CN1863763A (en) * | 2003-08-08 | 2006-11-15 | 拉卓拉药物公司 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and vap-1 mediated adhesion useful for treatment of diseases |
| WO2007120528A3 (en) * | 2006-03-31 | 2008-07-24 | Jolla Pharma | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
-
2017
- 2017-12-29 CN CN201711467947.3A patent/CN107935993A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| CN1520290A (en) * | 2001-07-12 | 2004-08-11 | �Ƹ��� | Carbocyclic hydrorazino inhibitors of copper-containing amine oxidases |
| WO2004024711A1 (en) * | 2002-09-10 | 2004-03-25 | Pharmacia Italia S.P.A. | Substituted pyridine derivatives as antitumor agent |
| CN1863763A (en) * | 2003-08-08 | 2006-11-15 | 拉卓拉药物公司 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and vap-1 mediated adhesion useful for treatment of diseases |
| WO2007120528A3 (en) * | 2006-03-31 | 2008-07-24 | Jolla Pharma | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11472769B2 (en) | 2019-10-29 | 2022-10-18 | Eccogene (Shanghai) Co., Ltd. | SSAO inhibitors and use thereof |
| US11964942B2 (en) | 2019-10-29 | 2024-04-23 | Eccogene (Shanghai) Co., Ltd. | SSAO inhibitors and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107935993A (en) | Methyl adamantane and nitropyridine structural derivative, Its Preparation Method And Use | |
| CN108003166A (en) | Containing piperazinyl and piperazine triazole type structural compounds, preparation method and its usage | |
| CN108047213A (en) | A kind of two ring nitrile compounds of the fluorine thiophene of sulfur-bearing ring and application thereof | |
| CN107935991A (en) | A kind of methyl adamantane and amido pyridine structure derivative, Its Preparation Method And Use | |
| CN107915719A (en) | SSAO inhibitor of a kind of methyl adamantane and pyridine structure and application thereof | |
| CN108033945A (en) | A kind of adamantane and nitropyridine structural compounds and purposes | |
| CN108191825A (en) | A kind of methyl adamantane and nitropyridine structural derivative and application thereof | |
| CN107935989A (en) | Adamantane and itrile group pyridine structure compound, preparation method and the usage | |
| CN107935992A (en) | One kind contains adamantane and haloperidid structural compounds and purposes | |
| CN108191824A (en) | A kind of methyl adamantane and dimethylaminopyridine structural derivative, Its Preparation Method And Use | |
| CN108033946A (en) | A kind of SSAO inhibitor, preparation method and its usage containing adamantane structure | |
| CN107935990A (en) | Containing adamantane and alcoxyl pyridine structure compound, preparation method and the usage | |
| CN108003169A (en) | One kind contains morpholine and piperazine triazole class compounds and application thereof | |
| CN108003168A (en) | A kind of compound of nitrobenzene piperazine triazole structure and application thereof | |
| CN108129458A (en) | A kind of adamantane and dimethylaminopyridine structural derivative, preparation method and the usage | |
| CN108003171A (en) | Containing morpholine and piperazine triazole class compounds, preparation method and its usage | |
| CN107903271A (en) | One kind contains morpholine and piperazine triazole class compounds, preparation method and its usage | |
| CN108003170A (en) | Containing morpholine and piperazine triazole derivative and application thereof | |
| CN108084154A (en) | A kind of adamantane and amido pyridine structure derivative, preparation method and the usage | |
| CN107936002A (en) | A kind of two ring nitrile compounds of isopropyl piperazine amido thiophene and application thereof | |
| CN108129457A (en) | A kind of adamantane SSAO inhibitor, preparation method and its usage | |
| CN108191823A (en) | A kind of alkyl substitution adamantane SSAO inhibitor, preparation method and its usage | |
| CN108003167A (en) | Piperazine triazole structure compound of second Propylpiperazine and application thereof | |
| CN108003148A (en) | Two ring nitrile compounds of isopropyl piperazine thiophene, preparation method and its usage | |
| CN108003147A (en) | Two ring nitrile compounds of isopropyl piperazine fluorine thiophene, preparation method and its usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180420 |
|
| WD01 | Invention patent application deemed withdrawn after publication |